Alnylam Pharmace. buy Maxi_Scalibusa
Summary
This prediction ended on 16.08.18 with a price of €82.67. The price of Alnylam Pharmace. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -27.30%. Maxi_Scalibusa has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | 11.101% | 11.101% | 42.467% | 44.742% |
iShares Core DAX® | -5.744% | -6.037% | 9.155% | 8.257% |
iShares Nasdaq 100 | -4.907% | -12.083% | 19.607% | 30.219% |
iShares Nikkei 225® | -7.230% | -10.182% | 3.445% | -1.121% |
iShares S&P 500 | -4.764% | -6.545% | 19.194% | 31.957% |
Comments by Maxi_Scalibusa for this prediction
In the thread Alnylam Pharmace. diskutieren
Hot Stock